Literature DB >> 10348718

Monocyte plasminogen activator inhibitor 2 (PAI-2) inhibits u-PA-mediated fibrin clot lysis and is cross-linked to fibrin.

H Ritchie1, L A Robbie, S Kinghorn, R Exley, N A Booth.   

Abstract

Plasminogen activator inhibitor 2 (PAI-2) is a major product of activated human monocytes. Here we show that monocytes inhibited u-PA- but not t-PA-mediated fibrinolysis, by secreting PAI-2 into an overlying fibrin clot. Extracts of arterial and venous human thrombi were found to contain active PAI-2. PAI-2 was cross-linked to fibrin in a reaction catalyzed by two major transglutaminases (TG), tissue TG and factor XIII. The activity of PAI-2 was not affected by such cross-linking. Cross-linking of PAI-2 to fibrin was inhibited by Tridegin, a specific inhibitor of TG, and also by EDTA and iodoacetamide. The use of competitive peptides mimicking the loop between helices C and D of PAI-2 identified Gln 83 and 86 as residues important in cross-linking. This study defines a mechanism by which PAI-2 is localized to fibrin, where it acts as an effective inhibitor of u-PA-mediated fibrinolysis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10348718

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  13 in total

1.  Coagulation factor XIIIa substrates in human plasma: identification and incorporation into the clot.

Authors:  Camilla Lund Nikolajsen; Thomas F Dyrlund; Ebbe Toftgaard Poulsen; Jan J Enghild; Carsten Scavenius
Journal:  J Biol Chem       Date:  2014-01-17       Impact factor: 5.157

2.  Provisional Matrix Deposition in Hemostasis and Venous Insufficiency: Tissue Preconditioning for Nonhealing Venous Ulcers.

Authors:  Tony J Parker; James A Broadbent; Jacqui A McGovern; Daniel A Broszczak; Christina N Parker; Zee Upton
Journal:  Adv Wound Care (New Rochelle)       Date:  2015-03-01       Impact factor: 4.730

Review 3.  Factor XIIIa inhibitors as potential novel drugs for venous thromboembolism.

Authors:  Rami A Al-Horani; Srabani Kar
Journal:  Eur J Med Chem       Date:  2020-05-18       Impact factor: 6.514

4.  Enhanced venous thrombus resolution in plasminogen activator inhibitor type-2 deficient mice.

Authors:  S A Siefert; C Chabasse; S Mukhopadhyay; M H Hoofnagle; D K Strickland; R Sarkar; T M Antalis
Journal:  J Thromb Haemost       Date:  2014-09-30       Impact factor: 5.824

5.  Regulation of plasminogen activation by TGF-beta in cultured human retinal endothelial cells.

Authors:  S M Wileman; N A Booth; N Moore; B Redmill; J V Forrester; R M Knott
Journal:  Br J Ophthalmol       Date:  2000-04       Impact factor: 4.638

6.  The antifibrinolytic function of factor XIII is exclusively expressed through α₂-antiplasmin cross-linking.

Authors:  Steven R Fraser; Nuala A Booth; Nicola J Mutch
Journal:  Blood       Date:  2011-04-06       Impact factor: 22.113

7.  Functional factor XIII-A is exposed on the stimulated platelet surface.

Authors:  Joanne L Mitchell; Ausra S Lionikiene; Steven R Fraser; Claire S Whyte; Nuala A Booth; Nicola J Mutch
Journal:  Blood       Date:  2014-10-20       Impact factor: 22.113

8.  Model thrombi formed under flow reveal the role of factor XIII-mediated cross-linking in resistance to fibrinolysis.

Authors:  N J Mutch; J S Koikkalainen; S R Fraser; K M Duthie; M Griffin; J Mitchell; H G Watson; N A Booth
Journal:  J Thromb Haemost       Date:  2010-09       Impact factor: 5.824

9.  SerpinB2 inhibits migration and promotes a resolution phase signature in large peritoneal macrophages.

Authors:  Wayne A Schroder; Thiago D Hirata; Thuy T Le; Joy Gardner; Glen M Boyle; Jonathan Ellis; Eri Nakayama; Dilan Pathirana; Helder I Nakaya; Andreas Suhrbier
Journal:  Sci Rep       Date:  2019-08-27       Impact factor: 4.379

10.  Factor XIII deficiency does not prevent FeCl3-induced carotid artery thrombus formation in mice.

Authors:  Zhaoming Tang; Sravya Kattula; Lori A Holle; Brian C Cooley; Feng-Chang Lin; Alisa S Wolberg
Journal:  Res Pract Thromb Haemost       Date:  2019-11-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.